| Luo, Jianmin |
TE-ITP, NCT05583838: A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts |
|
|
| Completed | 4 | 157 | RoW | rhTPO, Recombinant human thrombopoietin, TPIAO, Eltrombopag, Eltrombopag olamine | Institute of Hematology & Blood Diseases Hospital, China, The Second Hospital of Hebei Medical University, Xijing Hospital, The Affiliated Hospital of Inner Mongolia Medical University, The Second Affiliated Hospital of Kunming Medical University, Second Affiliated Hospital of Guangzhou Medical University, Shaanxi Provincial People's Hospital, Henan Cancer Hospital, North China University of Science and Technology Affiliated Hospital, The Second Affiliated Hospital of Dalian Medical University, Second Hospital of Shanxi Medical University, The Second Affiliated Hospital of Harbin Medical University, Shenyang Sunshine Pharmaceutical Co., LTD., First Affiliated Hospital of Xinjiang Medical University, People's Hospital of Xinjiang Uygur Autonomous Region, Kashgar 1st People's Hospital, Xi'an Central Hospital, Beijing Public Health Foundation, Yuyao People's Hospital of Zhejiang Province | Previously Treated Primary Immune Thrombocytopenia | 02/24 | 07/24 | | |
NCT04626752: CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | 1 | 50 | RoW | BCMA CAR-T, senl_BCMA, Fludarabine, flu, Cyclophosphamide, ctx | Hebei Senlang Biotechnology Inc., Ltd. | Relapsed or Refractory Multiple Myeloma | 03/23 | 03/23 | | |
NCT04626765: CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 1 | 50 | RoW | CD19 CAR-T, Senl_19, CD22 CAR-T, Senl_22, CD 19+22, Senl_19+22, Fludarabine, flu, Cyclophosphamide, ctx | Hebei Senlang Biotechnology Inc., Ltd., The Second Hospital of Hebei Medical University | Childhood Acute Lymphoblastic Leukemia | 03/23 | 05/23 | | |
NCT04626739: CAR-T Cells in Treating Patients With Relapsed or Refractory NHL |
|
|
| Recruiting | 1 | 100 | RoW | CD19 CAR-T, Senl_19, CD22 CAR-T, Senl_22, CD19+CD22 CAR-T, Senl_19+22, Fludarabine, flu, Cyclophosphamide, ctx | Hebei Senlang Biotechnology Inc., Ltd. | Refractory Indolent Adult Non-Hodgkin Lymphoma | 03/23 | 03/23 | | |
NCT04626726: Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation |
|
|
| Recruiting | 1 | 50 | RoW | CD19 CAR-T, Senl_19, CD22 CAR-T, Senl_22, CD19+CD22 CAR-T, Senl_19+22, Fludarabine, fiu, Cyclophosphamide, ctx | Hebei Senlang Biotechnology Inc., Ltd. | Adult B Acute Lymphoblastic Leukemia | 05/23 | 05/23 | | |
| Li, Jianqiang |
NCT03312205: CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies |
|
|
| Recruiting | 1/2 | 50 | RoW | Autologous CAR-T cells | Hebei Senlang Biotechnology Inc., Ltd., Hebei Yanda Ludaopei Hospital, Beijing Lu Daopei Hospital | Leukemia, Lymphoma, Multiple Myeloma of Bone (Diagnosis) | 08/19 | 08/23 | | |
NCT04626765: CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 1 | 50 | RoW | CD19 CAR-T, Senl_19, CD22 CAR-T, Senl_22, CD 19+22, Senl_19+22, Fludarabine, flu, Cyclophosphamide, ctx | Hebei Senlang Biotechnology Inc., Ltd., The Second Hospital of Hebei Medical University | Childhood Acute Lymphoblastic Leukemia | 03/23 | 05/23 | | |
NCT04626752: CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | 1 | 50 | RoW | BCMA CAR-T, senl_BCMA, Fludarabine, flu, Cyclophosphamide, ctx | Hebei Senlang Biotechnology Inc., Ltd. | Relapsed or Refractory Multiple Myeloma | 03/23 | 03/23 | | |
NCT04626739: CAR-T Cells in Treating Patients With Relapsed or Refractory NHL |
|
|
| Recruiting | 1 | 100 | RoW | CD19 CAR-T, Senl_19, CD22 CAR-T, Senl_22, CD19+CD22 CAR-T, Senl_19+22, Fludarabine, flu, Cyclophosphamide, ctx | Hebei Senlang Biotechnology Inc., Ltd. | Refractory Indolent Adult Non-Hodgkin Lymphoma | 03/23 | 03/23 | | |
NCT04626726: Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation |
|
|
| Recruiting | 1 | 50 | RoW | CD19 CAR-T, Senl_19, CD22 CAR-T, Senl_22, CD19+CD22 CAR-T, Senl_19+22, Fludarabine, fiu, Cyclophosphamide, ctx | Hebei Senlang Biotechnology Inc., Ltd. | Adult B Acute Lymphoblastic Leukemia | 05/23 | 05/23 | | |
NCT04556669: Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors |
|
|
| Recruiting | 1 | 30 | RoW | Autologous aPD-L1 armored anti-CD22 CAR T cells | Hebei Senlang Biotechnology Inc., Ltd. | Solid Tumor, Adult, Cervical Cancer, Sarcoma, NSCLC | 08/23 | 08/25 | | |
NCT04447573: Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | N/A | 20 | RoW | BCMA CAR-T | Hebei Senlang Biotechnology Inc., Ltd., Beijing Ludaopei Hospital, Hebei Yanda Ludaopei Hospital | Multiple Myeloma | 08/22 | 12/22 | | |
NCT04447547: Clinical Trial of SL1904B CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma |
|
|
| Recruiting | N/A | 20 | RoW | CD19 CAR-T | Hebei Senlang Biotechnology Inc., Ltd., Beijing Ludaopei Hospital, Hebei Yanda Ludaopei Hospital | Non-hodgkin's Lymphoma | 08/22 | 12/22 | | |
NCT04546893: Safety and Efficacy Study of SL1904B CAR-T Cells for Relapsed or Refractory B-Cell Acute Lymphocyte Leukemia |
|
|
| Recruiting | N/A | 20 | RoW | CD19 CAR-T | Hebei Senlang Biotechnology Inc., Ltd., Hebei Yanda Ludaopei Hospital, Beijing Ludaopei Hospital | B-ALL | 09/22 | 12/22 | | |
NCT04546906: Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia |
|
|
| Recruiting | N/A | 20 | RoW | CD22 CAR-T | Hebei Senlang Biotechnology Inc., Ltd. | B-ALL | 09/22 | 12/22 | | |
NCT04610125: Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children |
|
|
| Recruiting | N/A | 30 | RoW | Auto CAR-T, Cyclophosphamide,Fludarabine, Leukapheresis | Hebei Senlang Biotechnology Inc., Ltd., Hebei Medical University Fourth Hospital | Leukemia, Lymphoma | 06/23 | 06/25 | | |
NCT04665063: A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma |
|
|
| Recruiting | N/A | 20 | RoW | Auto CAR-T, Cyclophosphamide,Fludarabine, Leukapheresis | Hebei Senlang Biotechnology Inc., Ltd., Hebei Medical University Fourth Hospital | Hodgkin's Lymphoma | 10/23 | 10/25 | | |
NCT04665076: Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors |
|
|
| Recruiting | N/A | 60 | RoW | Auto CAR-T, Cyclophosphamide,Fludarabine, Leukapheresis | Hebei Senlang Biotechnology Inc., Ltd., Hebei Medical University Fourth Hospital | Plasma Cell Tumors | 10/23 | 10/25 | | |
NCT04666168: A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma |
|
|
| Recruiting | N/A | 200 | RoW | Auto CAR-T, Cyclophosphamide,Fludarabine, Leukapheresis | Hebei Senlang Biotechnology Inc., Ltd., Hebei Medical University Fourth Hospital | Non-hodgkin's Lymphoma | 10/23 | 10/25 | | |
